From Batch to Flow: Embracing Continuous Manufacturing
Roots Analysis
Market research & consulting services in the pharma / biopharma, medical devices & contract manufacturing domains
CONTINUOUS MANUFACTURING MARKET SIZE
The global continuous manufacturing market is estimated to be worth $2,080 million in 2023. The global continuous manufacturing market is anticipated to grow at a CAGR of 6.4% during the forecast period. The new research study consists of industry trends, detailed market analysis, capacity analysis, patent analysis, grant analysis, recent expansions and partnerships and collaborations analysis. The growth in the continuous manufacturing market size over the next decade is likely to be driven by the myriad advantages offered by continuous manufacturing over traditional batch processing.
For decades, pharmaceutical companies have been using batch processing method for drug manufacturing, wherein a specific quantity of a drug is produced through multiple sequential steps. However, batch processing / batch manufacturing of a drug substance or drug products can be slow and inefficient. As a result, drug developers have begun to adopt continuous manufacturing systems to streamline drug production process. Continuous manufacturing involves the production of pharmaceutical drug substance / drug products in a single run, while operating 24×7. This technique offers several advantages over traditional batch processing, including reduction in facility footprint (by 70%), operational and running costs (by 40-50%) and easy scale up. Moreover, Food Drug Administration (FDA) is encouraging the adoption of continuous manufacturing system by publishing guidance documents focused on quality considerations of continuous manufacturing process and documents related to continuous manufacturing of drug substance and drug product.
For detailed information:
Email: [email protected]
Competitive Landscape of Small Molecule Continuous Manufacturing Companies
The small molecule continuous manufacturing companies landscape features close to 50 manufacturers having expertise in end to end continuous manufacturing or semi continuous manufacturing of drug products. The market landscape is well-fragmented, featuring the presence of small, mid-sized, large, and very large companies, which claim to have the required expertise in continuous small molecule API manufacturing and Finished Dosage Form (FDF) manufacturing. It is interesting to highlight that majority (~75%) of the small molecule manufacturers are focused on API manufacturing followed by the companies focused on FDF manufacturing. Further, more than 50% of the continuous small molecule manufacturers are based in Europe, followed by North America and Asia Pacific.
Competitive Landscape of Biologic Continuous Manufacturing Companies
Presently, close to 60 manufacturers have adopted end to end continuous manufacturing and semi-continuous manufacturing process for various types of biologics, including antibodies, enzymes, proteins / peptides, vaccines and viral vectors. It is interesting to note that close to 50% of these companies are large and very large firms, indicating the presence of well-established players in this market. Further, close to 75% of the continuous biologic manufacturers offer contract manufacturing services for continuous manufacturing of the above mentioned biologics. Majority of these manufacturers are headquartered in North America (~40%) followed by Europe and Asia Pacific. Additionally, it is important to highlight that, presently, biologics segment captures the majority share of the continuous manufacturing market.
领英推荐
Continuous Manufacturing Market Trends: Increase in Patent Publications Reflect the Rising Interest of Companies in Continuous Manufacturing Process
Close to 700 patents related to continuous manufacturing of small molecule and biologics have been filed, since 2020, highlighting the substantial efforts made by industry stakeholders and researchers in continuous manufacturing market. Around 40% of these patents were filed / granted in North America, followed by patents filed / granted under the jurisdiction of Asia Pacific and World Intellectual Property Organization (WIPO). In addition, the maximum number of patents focused on continuous manufacturing were filed by Genzyme, Boehringer Ingelheim, Amgen, EMD Millipore and Repligen.
Leading Companies in Continuous Manufacturing Market
Examples of key companies engaged in continuous manufacturing market include AbbVie Contract Manufacturing, ACG Group, Boehringer Ingelheim, Corden Pharma, Glatt Group, Kaneka, Phlow and Wuxi Biologics. This market report includes an easily searchable excel database of all the companies who have adopted continuous manufacturing either for biologics or small molecules.
All your Questions Related to Continuous Manufacturing Market Answered in this Report
The Continuous Manufacturing Market 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the continuous manufacturing market, during the given forecast period. The report answers many key questions related to this market. Click on the below link to know more about this emerging area of research.
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.